HCPCS Code Detail Logo

HCPCS Codes Similar to G0681

HCPCS Codes Similar to “G0681” Code.
Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less of wound surface area

G0682
Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)
Code added date: 20260401
Code effective date: 20260401
G0683
Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
Code added date: 20260401
Code effective date: 20260401
G0684
Application of a premarket approval (pma), 510(k), 361 human cells, tissues or cellular and tissue-based products (hct/p) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)
Code added date: 20260401
Code effective date: 20260401
Q4433
361 hct/p skin substitute product, not otherwise specified (list in addition to primary procedure)
Code added date: 20260101
Code effective date: 20260101
Q4431
Pma skin substitute product, not otherwise specified (list in addition to primary procedure)
Code added date: 20260101
Code effective date: 20260101
Q2055
Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code added date: 20220101
Code effective date: 20240404
Q4432
510(k) skin substitute product, not otherwise specified (list in addition to primary procedure)
Code added date: 20260101
Code effective date: 20260101
M0235
Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
Code added date: 20251001
Code effective date: 20251001
M0236
Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose
Code added date: 20251001
Code effective date: 20251001
Q0235
Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
Code added date: 20251001
Code effective date: 20251001
A6025
Gel sheet for dermal or epidermal application, (e.g., silicone, hydrogel, other), each
Code added date: 19970101
Code effective date: 20070101
A4100
Non-sheet form skin substitute, fda cleared as a device, not otherwise specified (list in addition to primary procedure)
Code added date: 20220401
Code effective date: 20260101
G9134
Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage i, ii at diagnosis, not relapsed, not refractory (for use in a medicare-approved demonstration project)
Code added date: 20070101
Code effective date: 20070101
G9135
Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage iii, iv, not relapsed, not refractory (for use in a medicare-approved demonstration project)
Code added date: 20070101
Code effective date: 20070101